Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Risk genes beyond APOE

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

We present a comprehensive global analysis of genetic variants associated with autosomal-dominant Alzheimer's disease (ADAD). A total of 550 variants in the APP, PSEN1 and PSEN2 genes were identified, of which 279 were classified as pathogenic or likely pathogenic based on American College of Medical Genetics and Genomics and the Association for Molecular Pathology criteria, utilizing data from the Dominantly Inherited Alzheimer Network (DIAN), literature and public databases. Symptomatic age at onset (AAO) data were estimated for 227 of these variants, allowing detailed characterization of their frequency, pathogenicity and AAO. Importantly, 226 variants met eligibility criteria for inclusion in disease-modifying clinical trials. Furthermore, we demonstrated the predictive value of mean variant AAO and parental AAO in predicting symptomatic AAO, validated against converters who became symptomatic during follow-up in the DIAN Observational Study. This dataset provides critical insights into the global landscape of ADAD and reveals the genetic and AAO heterogeneity of ADAD variants while refining variant trial eligibility criteria.

What this study adds

Evidence grade: Low

The record lists 550 participants. This global analysis identified 550 variants in APP, PSEN1 and PSEN2 associated with autosomal-dominant Alzheimer's disease, classified 279 as pathogenic or likely pathogenic, and estimated age at onset for 227 variants. It also found that mean variant age at onset and parental age at onset help predict symptomatic onset, which may refine eligibility for disease-modifying clinical trials, but the study itself does not test a treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Liu, H., Marsh, T. W., Shi, X., Renton, A. E., Bowling, K. M., Ziegemeier, E., et al. (2025). The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset. Brain. https://doi.org/10.1093/brain/awaf038

Vancouver

Liu H, Marsh TW, Shi X, Renton AE, Bowling KM, Ziegemeier E, et al. The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset. Brain. 2025. doi:10.1093/brain/awaf038. PMID: 39903689.

BibTeX

@article{liu2025-39903689,
  author  = {Liu, Haiyan and Marsh, Thomas W. and Shi, Xinyu and Renton, Alan Edward and Bowling, Kevin M. and Ziegemeier, Ellen and Wang, Guoqiao and Cao, Yuchen and others},
  title   = {{The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset}},
  journal = {Brain},
  year    = {2025},
  doi     = {10.1093/brain/awaf038},
  pmid    = {39903689},
  url     = {https://doi.org/10.1093/brain/awaf038}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This global analysis identified 550 variants in APP, PSEN1 and PSEN2 associated with autosomal-dominant Alzheimer's disease, classified 279 as pathogenic or likely pathogenic, and estimated age at onset for 227 variants. It also found that mean variant age at onset and parental age at onset help predict symptomatic onset, which may refine eligibility for disease-modifying clinical trials, but the study itself does not test a treatment or cure.

Study details

How this study scored 57/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 57 of 100.57 of 100 points earned43 not earned

Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Brain)
Journal's citation record 4 / 4 Brain: journal h-index 503 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 550 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 21 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.0 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 11.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 21 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Jorge J. Llibre‐Guerra: h-index 30 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 36 institution(s) in 10 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39903689)
Free to read 2 / 2 Free to read
Total 57 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Risk genes beyond APOE from nearby years

Also in Risk genes beyond APOE

102 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →